Loading stock…

Exor N.V. (EYX) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

EYXExor N.V.

Revenue FY25−$4.1B

GROWTH RATING↗

VERY WEAK2 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-145%1

Revenue, next 1Y-100%–

Revenue, next 3Y, CAGRna–

Revenue, next 5Y, CAGRna–

EARNINGS FORECAST▾SCORE

EPS growth, FY+10%5

EPS growth, FY+2+88%10

EPS growth, FY+3Loss1

GROWTH ASSESSMENT

STRENGTHS

After shrinking over the last 3 years, revenue is set to hold flat from here.

Earnings are set to grow faster than sales (EPS about 44%/yr vs revenue 0%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

Growth is the weak spot here, trailing 98% of companies worldwide.

Revenue fell 145%/yr over the last 3 years, behind 90% of companies worldwide.1/10

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

EYXExor N.V.

Total return Current94.9%

Price return Current84.3%

MOMENTUM RATING↗

WEAK23 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-7%4

3-month return-1%6

YTD return-4%4

MID & LONG-TERM▾SCORE

% of 52-week high81%5

1-year return-20%2

3-year return-15%2

5-year return-1%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Returns sit at the market level over the past month (-7%), over three months (-1%) and so far this year (-4%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-15% over three years and -0.8% over five), behind 70% of the market.

It's down 20% over the past year, now 19% below its 52-week high. That is a touch behind the market.

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Exor. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

EYXExor N.V.

Revenue FY25−$4.1B

GROWTH RATING↗

VERY WEAK2 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-145%1

Revenue, next 1Y-100%–

Revenue, next 3Y, CAGRna–

Revenue, next 5Y, CAGRna–

EARNINGS FORECAST▾SCORE

EPS growth, FY+10%5

EPS growth, FY+2+88%10

EPS growth, FY+3Loss1

GROWTH ASSESSMENT

STRENGTHS

After shrinking over the last 3 years, revenue is set to hold flat from here.

Earnings are set to grow faster than sales (EPS about 44%/yr vs revenue 0%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

Growth is the weak spot here, trailing 98% of companies worldwide.

Revenue fell 145%/yr over the last 3 years, behind 90% of companies worldwide.1/10

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's turning around. The one thing to watch: revenue has shrunk over the past 3 years.

03Price Momentum

Is the market behind it right now?

EYXExor N.V.

Total return Current94.9%

Price return Current84.3%

MOMENTUM RATING↗

WEAK23 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-7%4

3-month return-1%6

YTD return-4%4

MID & LONG-TERM▾SCORE

% of 52-week high81%5

1-year return-20%2

3-year return-15%2

5-year return-1%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Returns sit at the market level over the past month (-7%), over three months (-1%) and so far this year (-4%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-15% over three years and -0.8% over five), behind 70% of the market.

It's down 20% over the past year, now 19% below its 52-week high. That is a touch behind the market.

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Exor. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Exor N.V.

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on Exor. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on Exor. Get the full investment case.

Premium